Yanyan Tudor

Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck:  Synthesis, SAR, and in Vivo Anti-Inflammatory Activity

Erin F. DiMauro, John Newcomb, Joseph J. Nunes et al. · Journal of Medicinal Chemistry · 2006 · 67 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor

Ian McCaffery, Yanyan Tudor, Hongjie Deng et al. · Clinical Cancer Research · 2013 · 66 citations

Medicine, Oncology, Pharmacology +17

Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5′,4′:5,6]pyrimido[1,2-<i>a</i>]benzimidazol-5(6<i>H</i>)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity

Matthew W. Martin, John Newcomb, Joseph J. Nunes et al. · Journal of Medicinal Chemistry · 2008 · 64 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Novel 2-Aminopyrimidine Carbamates as Potent and Orally Active Inhibitors of Lck:  Synthesis, SAR, and in Vivo Antiinflammatory Activity

Matthew W. Martin, John Newcomb, Joseph J. Nunes et al. · Journal of Medicinal Chemistry · 2006 · 61 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase

Nuria Tamayo, Lillian Liao, Martin H. Goldberg et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 48 citations

Pharmacy, Medicinal Chemistry, Pharmacology +14